Belinostat NEW
| Price | $40 | $63 | $98 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Belinostat | CAS No.: 866323-14-0 |
| Purity: 99.75% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Belinostat |
| Description | Belinostat (PXD101) is an inhibitor of hydroxamic acid-type histone deacetylase (HDAC, IC50 of 27 nM in HeLa cell extracts),and with antineoplastic activity. |
| In vitro | Belinostat is a novel hydroxamate-type inhibitor of histone deacetylase activity that inhibits histone deacetylase activity in HeLa cell extracts with an IC(50) of 27 nM and induces a concentration-dependent (0.2-5 micro M) increase in acetylation of histone H4 in tumor cell lines.Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC(50)s in the range 0.2-3.4 micro M as determined by a clonogenic assay and induces apoptosis. |
| In vivo | Treatment of nude mice bearing human ovarian and colon tumor xenografts with PXD101 (10-40 mg/kg/day i.p.) for 7 days results in a significant, dose-dependent growth delay without obvious signs of toxicity. Growth delay is also observed in xenografts of cisplatin-resistant ovarian tumor cells. A significant increase in acetylation of H4 is detected in blood and tumor tissues 3 hours after treatment. These findings suggest that PXD101 has potential as a novel antitumor agent. |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 135 mg/mL (424.068 mM) |
| Keywords | Histone deacetylases | Inhibitor | HDAC | PX-105684 | PXD 101 | inhibit | Belinostat | PX 105684 | Autophagy |
| Inhibitors Related | Hydroxychloroquine | Guanidine hydrochloride |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Autophagy Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2800.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-21 | |
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-20 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY